United States - English - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - nebivolol hydrochloride (unii: jgs34j7l9i) (nebivolol - unii:030y90569u) - nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see clinical studies (14.1)]. nebivolol tablets may be used alone or in combination with other antihypertensive agents [see drug interactions (7)]. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nebivolol tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelin

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 10.9 mg (equivalent: nebivolol, qty 10 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 5.45 mg (equivalent: nebivolol, qty 5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 1.363 mg (equivalent: nebivolol, qty 1.25 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

United States - English - NLM (National Library of Medicine)

amerigen pharmaceuticals inc. - nebivolol hydrochloride (unii: jgs34j7l9i) (nebivolol - unii:030y90569u) - nebivolol 2.5 mg - nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see clinical studies (14.1) ]. nebivolol tablets may be used alone or in combination with other antihypertensive agents [see drug interactions (7) ]. lowering blood pressure reduces the risk of fatal and non fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nebivolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, su

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 10.9 mg (equivalent: nebivolol, qty 10 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 5.45 mg (equivalent: nebivolol, qty 5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 2.725 mg (equivalent: nebivolol, qty 2.5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 1.363 mg (equivalent: nebivolol, qty 1.25 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - nebivolol hydrochloride (unii: jgs34j7l9i) (nebivolol - unii:030y90569u) - nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see clinical studies (14.1)]. nebivolol tablets may be used alone or in combination with other antihypertensive agents [see drug interactions (7)]. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nebivolol tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelin